Bone Biologics CEO Issues Letter to Stockholders

Author's Avatar
Oct 25, 2022

%3Cb%3EBone+Biologics+Corporation%3C%2Fb%3E (NASDAQ: BBLG), a developer of orthobiologic products for spine fusion markets, today issued the following letter to stockholders from its President and Chief Executive Officer, Jeffrey Frelick.